Vertex’s VX-880 Receives the US FDA’s Fast Track Designation for T1D

 Vertex’s VX-880 Receives the US FDA’s Fast Track Designation for T1D

Vertex’s VX-880 Receives the US FDA’s Fast Track Designation for T1D

Shots:

  • The US FDA has granted FTD for VX-880 to treat T1D. The designation is designed to facilitate the development and expedite the review of treatments for serious condition and fill an unmet medical need
  • Additionally, the company has initiated P-I/II trial for VX-880 in ~17 patients who have T1D with severe hypoglycemia and impaired hypoglycemic awareness
  • VX-880 is the first investigational stem cell-derived therapy utilizing fully differentiated, insulin-producing pancreatic islet cells for the treatment of T1D

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: Industry Global News 24

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post